IP Library Patent Application 15061477
Patent Application
App. No. 15/061,477

PROCESS FOR PREPARING OXYCODONE COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/061,477
Abstract

In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.

Claims (35)

1 - 79 . (canceled)

80 . A process for preparing an oxycodone salt composition comprising less than 100 ppm 14-hydroxycodeinone, which process comprises steps of:

(a) titrating an oxycodone base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone with an acid under conditions sufficient to provide an oxycodone salt composition comprising less than 100 ppm 14-hydroxycodeinone; and

(b) isolating the oxycodone salt composition comprising less than 100 ppm 14-hydroxycodeinone.

81 . The process of claim 80 , wherein the conditions affect acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

82 . The process of claim 81 , wherein the conditions reduce the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to the 14-hydroxycodeinone.

83 . The process of claim 80 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone during the process.

84 . The process of claim 82 , comprising preferentially removing at least some of the 14-hydroxycodeinone.

85 . The process of claim 80 , wherein the acid comprises hydrochloric acid.

86 . The process of claim 80 , wherein step (a) is performed under reducing conditions.

87 . The process of claim 80 , wherein the process is for preparing an oxycodone hydrochloride salt composition.

88 . The process of claim 80 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition.

89 . The process of claim 80 , wherein the oxycodone salt composition is isolated by a process comprising crystallization.

90 . The process of claim 80 , wherein the oxycodone salt composition in step (a) comprises 0.25 ppm or more 14-hydroxycodeinone.

91 . The process of claim 80 , wherein the oxycodone salt composition in step (a) comprises 1 ppm or more 14-hydroxycodeinone.

92 . The process of claim 80 , wherein the oxycodone salt composition in step (a) comprises 5 ppm or more 14-hydroxycodeinone.

93 . A process for preparing an oxycodone salt composition, which process comprises steps of:

(a) titrating an oxycodone base composition comprising 8α,14-dihydroxy-7,8-dihydrocodeinone with an acid under conditions sufficient to provide an oxycodone salt composition that is substantially free of 14-hydroxycodeinone; and

(b) isolating the oxycodone salt composition that is substantially free of 14-hydroxycodeinone.

94 . The process of claim 93 , wherein the conditions affect acid catalyzed dehydration consisting of conversion of the 8α,14-dihydroxy-7,8-dihydrocodeinone to 14-hydroxycodeinone.

95 . The process of claim 94 , wherein the conditions reduce the rate of dehydration of the 8α,14-dihydroxy-7,8-dihydrocodeinone to the 14-hydroxycodeinone.

96 . The process of claim 93 , wherein at least some of the 8α,14-dihydroxy-7,8-dihydrocodeinone is dehydrated to 14-hydroxycodeinone during the process.

97 . The process of claim 96 , comprising preferentially removing at least some of the 14-hydroxycodeinone.

98 . The process of claim 93 , wherein the acid comprises hydrochloric acid.

99 . The process of claim 93 , wherein step (a) is performed under reducing conditions.

100 . The process of claim 93 , wherein the process is for preparing an oxycodone hydrochloride salt composition.

101 . The process of claim 93 , wherein the process is for preparing an oxycodone hydrochloride active pharmaceutical ingredient composition.

102 . The process of claim 93 , wherein the oxycodone salt composition is isolated by a process comprising crystallization.

103 . The process of claim 93 , wherein the isolated oxycodone salt composition comprises less than 25 ppm 14-hydroxycodeinone.

104 . The process of claim 103 , wherein the isolated oxycodone salt composition comprises less than 15 ppm 14-hydroxycodeinone.

105 . The process of claim 104 , wherein the isolated oxycodone salt composition comprises less than 10 ppm 14-hydroxycodeinone.

106 . The process of claim 93 , wherein the isolated oxycodone salt composition comprises 0.25 ppm or more 14-hydroxycodeinone.

107 . The process of claim 106 , wherein the oxycodone salt composition comprises 0.5 ppm or more 14-hydroxycodeinone.

108 . The process of claim 107 , wherein the oxycodone salt composition comprises 1 ppm or more 14-hydroxycodeinone.

109 . The process of claim 108 , wherein the oxycodone salt composition comprises 5 ppm or more 14-hydroxycodeinone.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: THE P.F. LABORATORIES, INC.; PURDUE PHARMA TECHNOLOGIES, INC.
To: PURDUE PHARMA L.P.
Reel/Frame 048936/0093 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: CHAPMAN, ROBERT; RIDER, LONN S.; HONG, QI; KYLE, DONALD; KUPPER, ROBERT
To: EURO-CELTIQUE S.A.
Reel/Frame 040033/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: EURO-CELTIQUE S.A.
To: PURDUE PHARMA L.P.
Reel/Frame 040034/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2016
From: PURDUE PHARMA L.P.
To: PURDUE PHARMA L.P.; THE P.F. LABORATORIES, INC.; PURDUE PHARMACEUTICALS L.P.; RHODES TECHNOLOGIES
Reel/Frame 040034/0442 →